Skip to main content

Peer-reviewed data shows Gilead's drug effective against COVID-19 -NIH

The National Institutes of Health (NIH) said on Friday peer-reviewed data published in the New England Journal of Medicine from a trial testing Gilead Sciences Inc's remdesivir showed the drug was superior to the standard of care for COVID-19.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.